PE20180035A1 - Tableta de ribociclib - Google Patents

Tableta de ribociclib

Info

Publication number
PE20180035A1
PE20180035A1 PE2017002096A PE2017002096A PE20180035A1 PE 20180035 A1 PE20180035 A1 PE 20180035A1 PE 2017002096 A PE2017002096 A PE 2017002096A PE 2017002096 A PE2017002096 A PE 2017002096A PE 20180035 A1 PE20180035 A1 PE 20180035A1
Authority
PE
Peru
Prior art keywords
ribociclib
tablet
reibociclib
piperazin
pyrrolo
Prior art date
Application number
PE2017002096A
Other languages
English (en)
Spanish (es)
Inventor
Bindhumadhavan Gururajan
Arnaud Grandeury
Rui Costa
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20180035(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20180035A1 publication Critical patent/PE20180035A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PE2017002096A 2015-04-16 2016-04-14 Tableta de ribociclib PE20180035A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562148240P 2015-04-16 2015-04-16

Publications (1)

Publication Number Publication Date
PE20180035A1 true PE20180035A1 (es) 2018-01-09

Family

ID=55806565

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017002096A PE20180035A1 (es) 2015-04-16 2016-04-14 Tableta de ribociclib

Country Status (29)

Country Link
US (6) US10799506B2 (enExample)
EP (3) EP4620458A3 (enExample)
JP (1) JP2018514523A (enExample)
KR (2) KR102750931B1 (enExample)
CN (2) CN115554257A (enExample)
AR (1) AR104257A1 (enExample)
AU (5) AU2016248017A1 (enExample)
BR (1) BR112017021283A2 (enExample)
CA (1) CA2982425C (enExample)
CL (1) CL2017002593A1 (enExample)
CO (1) CO2017010510A2 (enExample)
DK (1) DK3283058T3 (enExample)
EA (1) EA201792290A1 (enExample)
EC (1) ECSP17075052A (enExample)
ES (1) ES2938261T3 (enExample)
FI (1) FI3283058T3 (enExample)
HR (1) HRP20230053T1 (enExample)
HU (1) HUE061213T2 (enExample)
IL (1) IL254818A0 (enExample)
MX (1) MX2017013350A (enExample)
PE (1) PE20180035A1 (enExample)
PH (1) PH12017501820A1 (enExample)
PL (1) PL3283058T3 (enExample)
PT (1) PT3283058T (enExample)
SG (1) SG11201708084PA (enExample)
SI (1) SI3283058T1 (enExample)
TN (1) TN2017000422A1 (enExample)
TW (1) TW201642864A (enExample)
WO (1) WO2016166703A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018514523A (ja) * 2015-04-16 2018-06-07 ノバルティス アーゲー リボシクリブ錠剤
CA3048036A1 (en) 2018-07-02 2020-01-02 Apotex Inc Novel crystalline form of ribociclib succinate
EP4021450B1 (en) 2019-08-26 2025-11-05 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
IL293940A (en) 2019-12-16 2022-08-01 Lunella Biotech Inc Selective cancer drugs cdk4/6 inhibitors
CA3164619A1 (en) 2019-12-16 2021-06-24 Lunella Biotech, Inc. Selective cdk4/6 inhibitor cancer therapeutics
US20230310327A1 (en) * 2020-08-03 2023-10-05 Natco Pharma Limited Pharmaceutical compositions comprising ribociclib
KR20230079187A (ko) * 2020-09-29 2023-06-05 라보라토리오스 실레인즈, 에스.에이. 드 씨.브이. 고지혈증 및 심혈관 질환의 치료 및 예방을 위한 스타틴 및 피브레이트의 약학적 병용
WO2022162122A1 (en) 2021-01-29 2022-08-04 Biotx.Ai Gmbh Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
TWI848533B (zh) 2022-01-25 2024-07-11 瑞士商諾華公司 瑞博西尼藥物組成物
TWI866427B (zh) 2022-08-31 2024-12-11 美商亞文納營運公司 雌激素受體降解劑之給藥方案
EP4626890A1 (en) 2022-12-01 2025-10-08 KRKA, d.d., Novo mesto Ribociclib salts and formulations thereof
AU2024244511A1 (en) 2023-03-27 2025-09-25 Novartis Ag Method of treating early breast cancer with ribociclib in combination with an aromatase inhibitor
WO2025219830A1 (en) 2024-04-15 2025-10-23 Novartis Ag Pharmaceutical compositions of ribociclib

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5428812A (en) * 1977-08-09 1979-03-03 Yoshitomi Pharmaceut Ind Ltd Preparation of coated tablet
GB9414045D0 (en) 1994-07-12 1994-08-31 Berwind Pharma Service Moisture barrier film coating composition, method, and coated form
EP0771339B1 (en) * 1994-07-12 2003-10-15 BPSI Holdings, Inc. Dry moisture barrier film coating composition, method of coating substrates using the same and pharmaceutical tablets coated therewith
US6448323B1 (en) * 1999-07-09 2002-09-10 Bpsi Holdings, Inc. Film coatings and film coating compositions based on polyvinyl alcohol
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
US8343533B2 (en) * 2009-09-24 2013-01-01 Mcneil-Ppc, Inc. Manufacture of lozenge product with radiofrequency
US20120115878A1 (en) 2010-11-10 2012-05-10 John Vincent Calienni Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
EA025033B1 (ru) * 2011-02-11 2016-11-30 Уиста Лэборэтэриз Лтд. Диаминиевые соли фенотиазина и их применение
IN2015DN01046A (enExample) * 2012-07-13 2015-06-26 Gtx Inc
EP3251673A1 (en) * 2012-12-13 2017-12-06 IP Gesellschaft für Management mbH Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
WO2014097125A1 (en) * 2012-12-20 2014-06-26 Novartis Ag Pharmaceutical combination comprising binimetinib
PT2976106T (pt) * 2013-03-21 2021-05-26 Array Biopharma Inc Terapia de combinação que compreende um inibidor de b-raf e um segundo inibidor
EP2810644A1 (en) * 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
JP2018514523A (ja) * 2015-04-16 2018-06-07 ノバルティス アーゲー リボシクリブ錠剤
CN109953966A (zh) * 2017-12-26 2019-07-02 天津耀辰实业发展有限公司 一种含有瑞博西尼的药物组合物及其制备方法
JP7347388B2 (ja) 2020-09-25 2023-09-20 信越化学工業株式会社 紫外線硬化型有機変性シリコーン組成物および硬化物

Also Published As

Publication number Publication date
AU2020250190A1 (en) 2020-11-05
US20250134893A1 (en) 2025-05-01
ECSP17075052A (es) 2018-02-28
SI3283058T1 (sl) 2023-03-31
BR112017021283A2 (pt) 2018-06-26
CN107530292A (zh) 2018-01-02
EP4620458A2 (en) 2025-09-24
KR20250009572A (ko) 2025-01-17
AU2024227794A1 (en) 2024-11-21
KR102750931B1 (ko) 2025-01-09
US20250127785A1 (en) 2025-04-24
US12064434B2 (en) 2024-08-20
AR104257A1 (es) 2017-07-05
SG11201708084PA (en) 2017-10-30
EP3283058A1 (en) 2018-02-21
CL2017002593A1 (es) 2018-05-18
EP4197530B1 (en) 2025-11-12
CO2017010510A2 (es) 2018-03-20
CA2982425C (en) 2023-10-31
EA201792290A1 (ru) 2018-02-28
AU2022215155B2 (en) 2024-08-01
PL3283058T3 (pl) 2023-03-20
CN107530292B (zh) 2022-11-01
AU2022215155A1 (en) 2022-09-01
ES2938261T3 (es) 2023-04-05
TN2017000422A1 (en) 2019-01-16
EP4197530A1 (en) 2023-06-21
PH12017501820A1 (en) 2018-04-23
TW201642864A (zh) 2016-12-16
US20250090531A1 (en) 2025-03-20
IL254818A0 (en) 2017-12-31
US12419894B2 (en) 2025-09-23
US20180071292A1 (en) 2018-03-15
US10799506B2 (en) 2020-10-13
FI3283058T3 (fi) 2023-03-01
HUE061213T2 (hu) 2023-05-28
EP4620458A3 (en) 2025-10-22
WO2016166703A1 (en) 2016-10-20
DK3283058T3 (da) 2023-02-13
AU2019201929B2 (en) 2020-07-09
JP2018514523A (ja) 2018-06-07
KR20170137101A (ko) 2017-12-12
HRP20230053T1 (hr) 2023-03-03
CA2982425A1 (en) 2016-10-20
US20200390771A1 (en) 2020-12-17
AU2019201929A1 (en) 2019-04-11
US20230104792A1 (en) 2023-04-06
MX2017013350A (es) 2018-01-25
PT3283058T (pt) 2023-02-03
AU2016248017A1 (en) 2017-10-19
EP3283058B1 (en) 2022-11-16
CN115554257A (zh) 2023-01-03

Similar Documents

Publication Publication Date Title
PE20180035A1 (es) Tableta de ribociclib
DOP2015000206A (es) Derivados de pirrolo[2,3-d]pirimidina como inhibidores de quinasas janus (jak)
UY37781A (es) Proceso para la preparación de pirazolo[1,5-a] pirimidinas y sales de las mismas
JO3670B1 (ar) ملح سكسينات من 7-سيكلوبنتيل -2- (5-بيبرازين-1-يل-بيريدين-2-يل أمينو) -7h-بيرولو [2، 3-d] بيريميدين -6-ثنائي ميثيل أميد حمض الكربوكسيل وعمليات تصنيعه
MX2015016513A (es) Bisulfato del inhibidor de la janus quinasa (jak) y metodo de preparacion para el mismo.
EP3172214A4 (en) 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
CO2017008924A2 (es) Sales de inhibidor de pi3k y procesos de preparación
EA201890820A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ДВОЙСТВЕННЫХ ИНГИБИТОРОВ DYRK1/CLK1
BR112013019223A2 (pt) forma de dosagem para liberação modificada, processo para a fabricação de um comprimido e processo para a fabricação de uma forma de dosagem oral
GT201400196A (es) Compuestos de heterociclilo
CL2015002304A1 (es) Formas del metil {4,6-diamino-2- [1- (2-fluorobencil)-1h-pirazolo [3,4-b] piridino-3-il] pirimidino-5-il} metil carbamato
CO6741203A2 (es) Derivados de biciclo[3,2,1]octilamida y sus usos
MX2019008815A (es) Sintesis de un inhibidor de tirosina quinasa de bruton.
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
AR100818A1 (es) N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida
CR20160400A (es) Derivados de nucleosido sustituidos con 4´-difluorometilo como inhibidores de la replicación de arn de la influenza
CL2019001694A1 (es) Compuestos de pirazolopirimidina y métodos de uso de los mismos.
WO2014153495A9 (en) Novel stat3 inhibitors
MX2020004148A (es) Sales cristalinas de un inhibidor de cinasa de fibrosarcoma acelerado rapidamente (b-raf).
GT201500292A (es) Formas cristalinas de inhibidores de tirosina cinasa y sus sales
EP3196199A4 (en) Substituted n-(pyrrolidine-3-yl)-7h-pyrrolo[2,3-d]pyrimidine-4-amine as janus kinase inhibitor
CU20150176A7 (es) Derivados de prodroga de triazolpiridinas sustituídas
ES2502140T1 (es) Comprimidos de liberación inmediata de rasagilina hemitartrato
MX2018009758A (es) Uso de inhibidores de la actividad o funcion de pi3k para el tratamiento del sindrome primario de sjögren.
TH1501004773A (th) อนุพันธ์ไพร์โรโล[2,3-d]ไพริมิดีนเป็นที่สารยับยั้งของไคเนสที่สัมพันธ์กับเจนัส (jak)